Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amgen (AMGN) PT Raised to $195 at Argus on 2Q Report; 'Contributors to Top-Line Growth: Kyprolis, Prolia & Sensipar'
July 27, 2017 10:11 AM EDTArgus raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Buy rating, following the company's second quarter earnings report.
Analyst David Toung notes the company delivered second quarter earnings per share and revenue results above consensus projections fueled by several... More
Amgen (AMGN) PT Raised to $180 at UBS Following Solid 2Q
July 26, 2017 8:34 AM EDTUBS raised its price target on Amgen (NASDAQ: AMGN) to $180.00 (from $175.00) while maintaining a Neutral rating. 2Q results were better than expectations with a $145M top-line beat. EPS also beat consensus estimates by $0.18.
UBS increased 2017 Enbrel sales estimates to $5.38B from $5B... More
Amgen (AMGN) PT Raised to $174 at Deutsche Bank
July 26, 2017 6:18 AM EDTDeutsche Bank raised its price target on Amgen (NASDAQ: AMGN) to $174.00 (from $172.00) while maintaining a Hold rating.
Analyst Andrew Peters called the quarter "solid" but said the near term outlook remains challenged.
"While the results beat expectations, we remain cautious on... More
